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Background: India currently has more than 60 million people with Type 2 Diabetes Mellitus (T2DM) and this is
predicted to increase by nearly two-thirds by 2030. While management of those with T2DM is important, preventing or
delaying the onset of the disease, especially in those individuals at ‘high risk’ of developing T2DM, is urgently needed,
particularly in resource-constrained settings. This paper describes the protocol for a cluster randomised controlled trial
of a peer-led lifestyle intervention program to prevent diabetes in Kerala, India.
Methods/design: A total of 60 polling booths are randomised to the intervention arm or control arm in rural Kerala,
India. Data collection is conducted in two steps. Step 1 (Home screening): Participants aged 30–60 years are
administered a screening questionnaire. Those having no history of T2DM and other chronic illnesses with an Indian
Diabetes Risk Score value of ≥60 are invited to attend a mobile clinic (Step 2). At the mobile clinic, participants
complete questionnaires, undergo physical measurements, and provide blood samples for biochemical analysis.
Participants identified with T2DM at Step 2 are excluded from further study participation. Participants in the control arm
are provided with a health education booklet containing information on symptoms, complications, and risk factors of
T2DM with the recommended levels for primary prevention. Participants in the intervention arm receive: (1) eleven
peer-led small group sessions to motivate, guide and support in planning, initiation and maintenance of lifestyle
changes; (2) two diabetes prevention education sessions led by experts to raise awareness on T2DM risk factors,
prevention and management; (3) a participant handbook containing information primarily on peer support and its role
in assisting with lifestyle modification; (4) a participant workbook to guide self-monitoring of lifestyle behaviours, goal
setting and goal review; (5) the health education booklet that is given to the control arm. Follow-up assessments are
conducted at 12 and 24 months. The primary outcome is incidence of T2DM. Secondary outcomes include behavioural,
psychosocial, clinical, and biochemical measures. An economic evaluation is planned.
Discussion: Results from this trial will contribute to improved policy and practice regarding lifestyle intervention
programs to prevent diabetes in India and other resource-constrained settings.
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Globally, India has the second largest number of individ-
uals with Type 2 Diabetes Mellitus (T2DM) (63 million),
and this is expected to rise to 101.2 million by 2030 [1].
While management of those already diagnosed with
T2DM is important, preventing or delaying the onset of
the disease, especially in those individuals at ‘high risk’
of developing T2DM, is needed to control the growth of
the disease [2], particularly in resource-constrained set-
tings [3]. Thus, the prevention of T2DM, through a
combination of individual-, community- and population-
based approaches needs urgent attention.
The efficacy of lifestyle interventions at preventing or
delaying the onset of T2DM is well-established [4-11].
Aziz et al., reported around 30 implementation trials
that have demonstrated a reduction in T2DM incidence
of between 40-60% compared with the control arm.
However, these trials have mainly been conducted in
high-income countries [Aziz et al. 2013, unpublished
data]. Indeed, the non-pharmacological and behavioural
intervention methods used in these trials have been
shown to be more cost-effective than drug treatment
[12,13], particularly when delivered via groups [14].
In India, diabetes prevention trials conducted to date
have primarily targeted those with impaired glucose toler-
ance (IGT) or impaired fasting glucose (IFG) [10,15].
However, in resource-constrained settings, it is important
to use a risk tool that is valid, reliable, low cost, quick and
easy to administer to identify the individuals at ‘high risk’
of developing T2DM rather than with the use of labora-
tory testing. The Indian Diabetes Prevention Programme
(IDPP-1) was a three-year randomised controlled trial
among an urban population with persistent IGT that im-
plemented a lifestyle intervention (individualised advice by
a health provider on healthy diet and regular physical ac-
tivity, with monthly telephone calls to maintain motiv-
ation) [10]. The sample selected was predominantly
middle class and from a restricted occupational setting.
Although the study was effective and showed a reduction
in T2DM incidence, the approach tested would be difficult
to ‘scale up’ to community or national level, i.e. it is not
feasible to provide one-on-one advice to the 21 million
people with IGT in India [1]. Furthermore, more than
two-thirds of India’s population lives in rural areas and ef-
fective approaches to diabetes prevention in this setting
require strategies that are less dependent on health care
providers and health care services. A lifestyle intervention
program by Balagopal et al., conducted under more ‘real
world’ conditions in a rural area, achieved an 11% reduc-
tion in fasting plasma glucose (FPG) levels in people with
IFG [15]. However, the study did not include a control
group and comprised small numbers with IFG.
To stem the growing epidemic of T2DM in India and
other resource-constrained settings, evidence is requiredregarding cost-effective community-based approaches
for screening and prevention that have high future scal-
ability. In our previous research, we have developed and
tested models for community interventions in Finland
and Australia. We have been able to show that group-
based approaches with underlying behaviour change the-
ory and strong emphasis on peer support will lead to
significant improvement in health behaviours and meta-
bolic risk factors [16-19]. More broadly, substantial re-
search from around the world shows the effectiveness of
peer support in prevention and disease management
[20-24] as well as engaging audiences whom health pro-
motion programs often have difficulty reaching [25,26].
Adapted from these programs, the Kerala Diabetes Pre-
vention Program (K-DPP) is the first implementation
trial to evaluate a peer-led, group-based lifestyle inter-
vention program among individuals at ‘high risk’ of de-
veloping T2DM in rural India.
Methods/design
Study aims
Primary
To evaluate the effectiveness of a peer-led, group-based
lifestyle intervention on reducing T2DM incidence and
improving the behavioural, psychosocial, clinical, and
biochemical measures at 24 months, compared with the
control arm.
Secondary
(i) To estimate the cost and cost-effectiveness of the
intervention in reducing the T2DM incidence and
improving quality of life.
(ii) To determine the reach, dose delivered, dose
received and fidelity of the intervention.
(iii) To identify the individual-, household-, and
neighbourhood-level factors likely to influence the
scalability of K-DPP in India and other resource-
constrained settings in the future.
Study design and setting
The study is a cluster randomised controlled trial, imple-
mented and reported in accordance with the Consoli-
dated Standards of Reporting Trials (CONSORT)
statement [27] and its extension to cluster randomised
trials [28]. The study is conducted in 60 polling booths
(PBs) in Neyyatinkara taluk (taluk is the administrative
unit below the district level in rural areas), Thiruva-
nanthapuram district, in the state of Kerala. Figure 1
shows the study area of K-DPP. The epidemiological
transition in Kerala is more advanced than elsewhere in
India [29]; indeed it has the largest proportion of those
with several major risk factors for non-communicable
diseases (NCDs) [30,31]. The state has a population of
Kerala state, India                                              Thiruvananthapuram district, Kerala     Neyyatinkara taluk, Thiruvananthapuram
Figure 1 Study area of the Kerala diabetes prevention program.
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38,863 square kilometers with a literacy rate of 93.9%,
life expectancy of 74.6 years, and sex ratio of 1084 females
per 1000 males [32]. Given the stage of epidemiological
transition, Kerala is likely to be a ‘harbinger’ of what will
happen in the future to the rest of India in terms of NCDs
[33,34]. Therefore, Kerala provides an appropriate place toRandomisatio
Step 1: Home screening (n = 80/P
Intervention arm (17 participants per PB)
(i) Eleven peer  led small group sessions
(ii) Two diabetes prevention education sessions
(iii) Participant handbook
(iv) Participant workbook
(v) Health education booklet
Follow-up mobile clinics (12 and 24 months): 
questionnaires, blood pressure, anthropometry, 
and biochemical tests
Neyyatinkara
Thiruvananthapuram
Random selection of 6
Step 2: Mobile clinic (n = 25/PB;
-
Figure 2 CONSORT diagram of the Kerala diabetes prevention prograimplement and evaluate a community-based diabetes pre-
vention program in India. Figure 2 is a CONSORT dia-
gram of the study design.
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IEC-333/May 2011) and the Human Research Ethics
Committee of Monash University, Australia (CF11/0457-
2011000194). The study was also approved by the Health
Ministry Screening Committee of the government of
India. Written informed consent is also obtained from all
the study participants.
Sample size calculations
The IDPP-1 study offers the best estimate for the incidence
of T2DM in the control arm, 18.3% per year [10]. Our pre-
cision calculations are based on the Poisson distribution,
allowing for an average of 15 participants per polling booth
enrolled at baseline and followed-up after two years. An
intra-class correlation coefficient for FPG measurements of
0.02 has been assumed [35]. For a significance level of 5%
and Type II error of 20% (i.e. power = 80%), allowing a loss
to follow-up of 10%, the numbers of participants and PBs
per arm required are 510 and 30 respectively for a feasible
and clinically significant relative risk of 0.70, i.e. reduction
by 30% in the proportion of participants with incident
T2DM after two years. Thus, our target recruitment is 60
PBs and 17 participants per PB.
Sample selection procedures
Clusters
Neyyatinkara taluk has four legislative assembly constituen-
cies (LACs) with 603 PBs. Unfortunately there was no map
available that showed the contiguous PBs across the LAC
borders, therefore PBs that lie along the borders of LACs
(244) were removed and 60 PBs (15 from each LAC) were
randomly selected from the remaining 359 PBs. The 15 PBs
in each LAC were then randomised to the intervention
arm or control arm. This was done by a biostatistician who
was blind to all other characteristics of the sampled units
and by using a constant block size and stratified by the size
of PB (approximately 900–1500 people aged ≥18 years/PB),
using Stata statistical software, Release 12. Contiguous PBs
were replaced by the next PB to preclude the risk of con-
tamination across boundaries of the PB.
Participants
The pilot study revealed that it is essential to approach
more males than females because males tended to be
unavailable during home screening (Step 1 of data col-
lection) as they work away from home and their partici-
pation rate was low in mobile clinics (Step 2 of data
collection). To obtain 17 participants per PB (approxi-
mately equal number of males and females), 80 individ-
uals (50 males and 30 females) aged 30–60 years
selected randomly from the electoral roll are approached
during home screening. The electoral roll is in the public
domain with details of name, age, sex, and address and
is updated every five years. Of those screened and whomeet the eligibility criteria, 25 individuals (15 males and
10 females) are invited to attend a mobile clinic. This re-
cruitment strategy is based on three assumptions: 1)
20% (n = 16) of the 80 individuals will not meet the eligi-
bility criteria at Step 1; 2) 57% (n = 37) of those eligible
at Step 1 will not be classified as ‘high risk’ of having
T2DM according to the Indian Diabetes Risk Score
(IDRS) with a cut-off value of ≥60 [36]; and 3) Approxi-
mately 8 to 10 participants will be classified as having
T2DM based on the sensitivity of IDRS (72.5%) [36] and
the awareness of diabetes (63.7%) [33] and therefore ex-
cluded at Step 2.
Study eligibility criteria
Eligible participants comprise randomly selected males
and females on the electoral roll from the selected PBs,
aged 30 to 60 years, and able to speak, read and write
Malayalam (the local language). Participants are ex-
cluded if they have prior diagnosis of T2DM, myocardial
infarction, heart failure, stroke, cancer, epilepsy, arthritis
or dementia, or currently use medications known to
affect glucose tolerance (glucocorticoids, anti-psychotic
drugs and anti-retroviral drugs). Pregnant women are
also excluded. Those at baseline diagnosed with T2DM,
based on a 2 hour oral glucose tolerance test (OGTT)
are excluded, and referred to a government healthcare
facility for further management. Diabetes is diagnosed
on the basis of fasting plasma glucose ≥ 126 mg%
(7.0 mmol/L) and/or post glucose load ≥ 200 mg%
(11.1 mmol/L) as per the World Health Organisation
(WHO) criteria [37].
Data collection
Data collection is conducted in four waves (each wave
consists of one LAC with 15 PBs). There are two steps
in data collection namely, home screening and mobile
clinic. The data collectors are given training prior to the
commencement of data collection and refresher training
after each wave using a training manual developed in ac-
cordance with the WHO STEPS (Stepwise approach to
surveillance) training guide [38]. Table 1 shows the
measurement domains, tools and time points (baseline,
12 and 24 months) at which data are collected.
Step 1: Home screening
The participants receive home visits from the data col-
lectors. After obtaining the written informed consent, a
screening questionnaire consisting of eligibility criteria
and the IDRS is administered. The IDRS is a diabetes
screening tool which creates a score of between 0 and
100, based on age, family history of diabetes, physical ac-
tivity, and waist circumference [36]. Waist and hip cir-
cumferences are measured using a Seca measuring tape
(model 201) in a private area of the household in
Table 1 Measurement domains, tools, and data collection time points (baseline, 12 months and 24 months)
Variable Component Measurement tools/questions Baseline 12 months 24 months
Socio-demographic measures Age, sex, marital status, education, religion, occupation,
household size, and monthly household expenditure
✓ ✓ ✓
Behavioural measures Tobacco use WHO STEPS questionnaire [38] ✓ ✓ ✓
Alcohol use WHO STEPS questionnaire [38] ✓ ✓ ✓
Physical activity Global Physical Activity Questionnaire [39] ✓ ✓ ✓
Sedentary behaviour Time spent in front of a screen [40] ✓ ✓ ✓
Diet Food Frequency Questionnaire adapted from
PROLIFE study [41]
✓ ✓ ✓
Diabetes knowledge Barriers to healthy eating Scale designed for trial ✓ ✓ ✓
Barriers to physical activity Adapted from the scale designed by Booth et al. [42] ✓ ✓ ✓
Self-efficacy (diet and
physical activity)
Adapted from the Nutrition and physical Activity
self-efficacy scales designed by Schwarzer and Renner [43]
✓ ✓ ✓
Psychosocial measures Depression Patient Health Questionnaire-9 amended in line with
CURES-65 study [44]
✓ ✓ ✓
Stress Chronic stress scale used in MESA study [45,46] ✓ ✓ ✓
Anxiety General anxiety disorder scale [47] ✓ ✓ ✓
Health-related quality of life Short Form-36 [48] ✓ ✓ ✓
Social support ENRICHD social support scale [49] ✓ ✓ ✓
Life satisfaction How satisfied are you with your life as a whole? ✓ ✓ ✓
Medical history Use of any medications, family history of diabetes, heart
disease or stroke, history of hypertension, and history
of high cholesterol
✓ ✓ ✓
Clinical measures Anthropometry Waist circumference (Seca measuring tape) [38]
Hip circumference [38]
✓ ✓ ✓
Height (Seca stadiometer) [38] ✓ ✓ ✓
Weight (TANITA body composition analyser) [38] ✓ ✓ ✓
Bioimpedance (TANITA body composition analyser) [38] ✓ ✓ ✓
Blood pressure Omron automatic blood pressure monitor [38] ✓ ✓ ✓
Biochemical measures Pathology Glycaemic control (fasting plasma glucose and 2 hour
post load glucose, HbA1c), lipid profile (total cholesterol,
HDL, LDL, triglycerides), and fibrinogen
✓ ✓ ✓
Cost effectiveness analysis Healthcare utilisation Direct and indirect costs associated with outpatient and
inpatient healthcare services, sources of financing, and
time away from work due to ill health
✓ ✓ ✓
Program evaluation Knowledge assessment Pre and post test ✓
Training evaluation Appropriateness of training ✓
Group session evaluation Quality, appropriateness and usefulness of group sessions,
engagement/involvement and ongoing support
4 months 8 months 12 months
Other evaluation Use of peer leader workbook, participant handbook,
implementation fidelity and challenges and barriers
4 months 8 months 12 months
Abbreviations: WHO STEPS World Health Organization Stepwise approach to surveillance, PROLIFE Population registry of lifestyle diseases, CURES Chennai urban
rural epidemiological study, MESA Multi-ethnic study of atherosclerosis, ENRICHD Enhancing recovery in coronary heart disease, HbA1c Glycosylated haemoglobin,
HDL High density lipoprotein, LDL Low density lipoprotein.
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waist circumference is measured over bare skin at the
midpoint between the lower margin of the last palpable
rib and the top of the iliac crest. Hip circumference is
taken at the maximum circumference over the buttocks
over light clothing. Participants who meet the eligibility
criteria with an IDRS value of ≥ 60 are invited to attend
a mobile clinic in their community. Those who are not
eligible are excluded from further study participation.Questionnaires are checked for completeness on a daily
basis by a local resource person (LRP).
Step 2: Mobile clinic
The clinics run from 6.00 am to approximately 10.30 am
on Saturdays and Sundays. Community buildings such
as schools, church halls, anganwadis (mother and child-
care centre), halls in primary health centres, panchayat
(local government office in rural areas) halls, and youth
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staffed by the project manager or study coordinator,
seven data collectors, two laboratory technicians, and
one LRP. The participant is registered in the clinic only
if they have fasted for 8–12 hours. If not, they are asked
to attend the clinic in a nearby PB on another morning.
Questionnaires are administered to collect information
on socio-demographic, behavioural and psychosocial
measures, diabetes knowledge, healthcare utilisation,
family history of chronic diseases, and use of medica-
tions. Questionnaires are checked for completeness prior
to the participant leaving the clinic. Blood pressure (BP)
and anthropometric measures (height, weight and
bioimpedance) are taken in accordance with the WHO
STEPS protocol [38]. Briefly for BP, the left mid-arm cir-
cumference is measured using a tape to determine the
appropriate cuff size. BP is recorded three times using
the Omron automatic blood pressure monitor (model
IA2) with a minimum of three minutes between the
readings. Height is measured using a Seca stadiometer
(model 213) while the participant is standing without
headgear and footwear, with feet together, heels against
the back board and knees straight, and looking straight
ahead [38]. Weight and bioimpedance are measured
using a TANITA body composition analyser (modelK-DPP Intervention components
Peer leaders
Participants
Two x 2-days group facilitation tr
delivered by the K-DPP intervent
Two diabetes prevention educatio
sessions by the expert panel mem
Peer leader workbook
Ongoing support from the K-DPP
intervention team
Participant handbook, participant
workbook and health education b
11 small group sessions
led by trained peer 
leaders
Ongoing support from a local res
person
Figure 3 Kerala diabetes prevention program intervention componenSC330) while the participant is standing still without
footwear, with one foot on each side of the scale, facing
forward, and arms at their side [38]. BP monitors are
calibrated weekly using a sphygmomanometer. Waist
and hip circumferences are repeated for 10% of the par-
ticipants for quality assurance. Blood samples are centri-
fuged at the clinic and transported to a laboratory
accredited by the National Accreditation Board for La-
boratories (NABL) [50] for processing. For external qual-
ity control, five percent of the blood samples are
transported to a laboratory accredited by NABL [50] and
College of American Pathologists (CAP) [51]. Partici-
pants with blood glucose values in the diabetic range are
excluded from further study participation and referred
to a government health care facility for further manage-
ment. Those without T2DM, i.e. those at ‘high risk’ of
developing T2DM are invited to continue their partici-
pation in the study. Participants complete assessments at
baseline, 12 and 24 months.
Study arms
Control arm
Participants in the control arm are provided with a
health education booklet containing information on
symptoms, complications, and risk factors of T2DMK-DPP Outcomes
aining 
ion team
n 
bers
 
 
ooklet
 
ource 
Participant outcomes
1. Behavioural outcomes
• Improved diet
• Increased physical activity
• Reduced tobacco use
• Reduced alcohol consumption
2. Psychosocial outcomes
• Reduced stress
• Improved quality of life
3. Clinical outcomes
• Reduced blood pressure 
• Reduced waist circumference
• Reduced body fat
4. Biochemical outcomes
• Reduced incidence of diabetes
• Improved glycaemic control 
• Improved lipid profile
Peer leader and Peer group outcomes
1. Increased provision of emotional and     
social support to /within the group
2. Increased utilization of community 
resources by the group
3. Increased linkages to social support 
networks of the group 
ts and outcomes.
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Participants are also given a copy of their blood pres-
sure, anthropometric and biochemical measurements
collected at baseline, 12 and 24 months with a recom-
mendation to consult a healthcare provider if the values
are abnormal.
Intervention arm
This is a multifaceted intervention delivered at multiple
levels as summarised in Figure 3. It has been developed
and culturally adapted based on our previous work
[16-19]. The main mode of delivery is peer-led, small
group sessions with training and ongoing support to the
peer leaders by the K-DPP intervention team (compris-
ing Intervention manager and Intervention assistant)
and practical support from LRPs nominated for each
group. Due to low levels of awareness of diabetes and its
prevention identified in our needs assessment study,
small group sessions are also complemented with two
diabetes prevention education sessions (DPES) [52]. Fur-
thermore, an expert panel is formed to meet information
needs identified in small groups. The lifestyle interven-
tion has been tested and modified based on a pilot inter-
vention with two groups in 2012–13.
a. Small group sessions
Small group sessions are planned with specific objectives
to support and lead the group in the lifestyle change
process. Participants are encouraged and reminded by
the LRPs to attend the sessions organised fortnightly till
session four and monthly from session five to session 13.
Meeting places and times are chosen with the group to
maximise convenience. The first session is an inaugural
meeting introducing the program and its potential bene-
fits to the participants and their families and is delivered
by the K-DPP intervention team. Participants are pro-
vided with a participant handbook and participant work-
book. The participants are further informed on DPES 1
scheduled within two weeks from the date of the first
session. Participants are encouraged to bring family
members to the DPES or send a family member prefera-
bly their spouse if they cannot attend the session.
Session 2 focuses on setting ground rules for the group
and identifies one male and one female peer leader. It
also prompts participants to recollect and consolidate
the information received from the DPES 1. The next 11
sessions are led by the peer leaders. During the sessions,
the group members discuss and share their behaviours,
set SMART (Specific, Measurable, Attainable, Relevant,
and Time-bound) goals, monitor and review goals. All
groups tackle diet and physical activity, but the specific
contents of the group sessions are flexible and depend
on each group’s needs. Suggested contents for diet cover
e.g., portion size, identifying cooking substitutions toreduce fat, increasing fruit and vegetable consumption,
and decreasing sugar intake, while contents for physical
activity include e.g., finding enjoyable activities for indi-
viduals and groups, incorporating those activities into
daily routines, and avoiding injuries/accidents. Tobacco
control and cessation, reducing alcohol consumption
and sleep are dealt with based on the participants’ needs
and interest. Furthermore, all groups discuss and identify
community-based and other resources that can be uti-
lized to support and sustain these behaviours. Weight
monitoring is also performed in the sessions. Peer
leaders and the participants are encouraged to partici-
pate in social activities such as walking groups and other
supports beyond the group sessions.
b. Diabetes prevention education sessions
DPES 1 and 2 are delivered by expert panel members
comprising of specialist advisors on diabetes, nutrition,
and physical activity. DPES 1, which is conducted within
two weeks after the first small group session, introduces
the participants to an understanding of T2DM and its
risk factors. The session primarily focuses on develop-
ment of T2DM and its risk factors, strategies for primary
and secondary prevention, misconceptions around
T2DM, and the role of lifestyle modification in preven-
tion of T2DM. The participants are also briefed on how
the K-DPP and peer support program will help them in
breaking the chain of disease for themselves and their
family members using community resources.
DPES 2, which is conducted within two weeks after
the third small group session, focuses specifically on the
risk factors that can be modified including behavior
change for diet, physical activity, sleep, alcohol use and
tobacco use and its effects on weight, waist circumfer-
ence, blood pressure and blood glucose.
c. Resource materials for participants
The participant handbook contains information about
peer support, objectives and benefits from attending
small group sessions, the role of peer support in assist-
ing with lifestyle modification, principles that guide a
group, who are the people at risk for T2DM, and risk
factors in detail. The participant workbook guides the
participants through 11 peer-led small group sessions
with self-monitoring of their lifestyle behaviours, goal
setting, goal review and ongoing group support. In
addition to the participant handbook and participant
workbook, participants also receive the health education
booklet that is given to the participants in control arm.
Participants are also provided with a non-elastic measur-
ing tape and are taught how to measure their waist cir-
cumference to assess the progress towards their goal.
The peer leaders of each group are given cups and
spoons to discuss with the group how to measure their
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and set targets.
d. Training and support for intervention delivery
Peer leader training (2 days) is conducted by the K-DPP
intervention team and aims to equip the peer leaders
with the following skills: group facilitation and commu-
nication skills, how to set and monitor goals for lifestyle
behaviours, goal setting and planning for healthy life-
style. Peer leaders are also instructed to maintain records
of every interaction with the participants and the K-DPP
intervention team. Peer leaders are provided with a peer
leader workbook, which describes the objectives of each
session with an activity guide and exercises for the peer
leader to improve communication and to lead the group
effectively in achieving their behavioural targets. In order
to reduce the engagement of the K-DPP intervention
team with the peer-led sessions, one refresher training
(2 days) is given to the peer leaders after session five to
share their experiences on conducting sessions and to
obtain guidance from other peer leaders. Peer leaders
are contacted by telephone before and after each session
to reflect on the sessions to be conducted and thereafter
to get feedback from the peer leaders on the participa-
tion of the group members. Face-to-face meetings with
groups of peer leaders are also organised at regular in-
tervals to facilitate ongoing support and communication
between the peer leaders and the K-DPP intervention
team and among the peer leaders.
Expert panel training (0.5 days) is conducted to inform
experts of the study details, the intervention program
and the behavioural targets.
Local resource person training (1 day) is conducted to
provide details of the program to the LRPs as well as to
advise them of the intervention components and discuss
their role as a facilitator of the peer-led small group ses-
sions.
Participants are also given a copy of their blood pres-
sure, anthropometric, and biochemical measurements
collected at baseline, 12 and 24 months with a recom-
mendation to consult a healthcare provider if the values
are found to be abnormal.
Outcome measures
The primary outcome measure is the incidence of
T2DM based on a single 2 hour OGTT. Secondary out-
come measures include: behavioural (tobacco use [38],
alcohol use [38], physical activity [39], sedentary behav-
iour [40], diet [41] and sleep), psychosocial (depression
[44], stress [45,46], anxiety [47], health-related quality of
life [48] and social support [49]), clinical (blood pressure
[38], waist circumference [38], body mass index [38] and
bioimpedance [38]), and biochemical (glycaemic control[fasting plasma glucose and 2 hour post glucose load,
and HbA1c], lipid profile and fibrinogen).
Program evaluation
Glasgow’s RE-AIM framework [53] is used to report on
the program’s reach, efficacy, adoption, implementation
and maintenance. For each dimension of the RE-AIM
framework, indicators for measurement have been devel-
oped, relevant data sources have been identified and the
appropriate data collection methods are implemented.
Evaluation tools have also been developed to measure
different features of the program implementation, in-
cluding program fidelity, acceptability and feasibility. In
the context of wider implementation and scale up in real
world settings, Pronk’s PIPE (penetration, implementa-
tion, participation, and effectiveness) Impact Metric [54]
will also be used to assess the impact of the program
from both a program administrative perspective and a
user or consumer perspective.
Economic evaluation
The economic evaluation of K-DPP will assess whether
the program offers value for money from the societal
perspective, thus includes costs incurred by the govern-
ment and also participants and their families. Detailed
information on healthcare resource use, and out of
pocket payments are collected at baseline and each
follow-up point. The questionnaires will also collect in-
formation on participants’ time away from employment
due to ill health. Healthcare resource use will be valued
using a primary costing study, given the absence of stan-
dardised published prices in India. The analysis will esti-
mate the cost for each participant in the trial, the
average cost per participant in each arm of the trial, as
well as the total cost of delivering the intervention. The
cost of the intervention will include the cost of setting
up, delivering and maintaining the intervention. These
estimates will be useful for future research assessing the
scalability of the program, and the potential budget im-
plications of implementing it into standard practice. Ef-
fectiveness will be measured in terms of screening
numbers needed to identify one case of ‘high risk’ for
developing diabetes and numbers needed to treat to pre-
vent or delay one case of diabetes. Incremental cost-
effectiveness ratios will be estimated comparing the
costs and outcomes. Sensitivity analysis will be under-
taken to test the robustness of the analysis in terms of
the cost inputs and health outcomes. Trial participants
are also completing the Short Form-36 (SF-36) at base-
line and follow-up. These can be converted into utility
weights using the SF-6D algorithm [55], which then
allow for the calculation of quality adjusted life years
(QALYs). Additional economic analyses will be employed
to estimate the cost per QALY gained. Currently there is
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erate one is planned. In the absence of a country-specific
algorithm, the UK, Australian and Singaporean algo-
rithms will each be used as robustness checks.
Data analyses
All analyses will be intention to treat, i.e. without regard
to the compliance of individuals within their allocated
study arm. Multiple imputation methods to infer missing
values for FPG and 2 hour post glucose load at follow-
up will be used. Analyses will be performed across the
imputed datasets and results will be combined using Sta-
ta’s “mi” commands. Analyses will adjust for clustering
by PB by calculating robust standard errors using the in-
formation sandwich formula. FPG at follow-up will be
compared between arms by analysis of covariance, adjust-
ing for baseline FPG. Logistic regression will compare 2-
year cumulative incidence of T2DM between arms. Cox
proportional hazards regression will compare time to dia-
betes onset between arms. The regression models will in-
clude adjustment for baseline measures, when comparing
outcomes between arms. All analyses will be performed in
Stata statistical software, Release 13.
Discussion
This paper describes the protocol for a cluster rando-
mised controlled trial of a peer-led lifestyle intervention
program to reduce incidence of T2DM among individ-
uals at ‘high risk’ of developing T2DM. The successful
implementation of this trial will contribute to improved
policy and practice regarding lifestyle intervention pro-
grams to prevent diabetes in India and other resource-
constrained settings.
Trial status
The trial is currently in the recruitment phase.
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